(firstQuint)Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.

5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis).

 Comparison of ARIXTRA cent in lower LImb Superficial Thrombophlebitis with placebo (CALISTO).

 An International, Multicentre, Randomised, Double-blind, Placebo-controlled, Two-parallel Group, Phase III Study to Evaluate the Efficacy and Safety of ARIXTRA (2.

5 mg subcutaneously) for the Treatment of Patients with Acute Symptomatic Isolated Superficial Thrombophlebitis of the Lower Limbs to prevent Thromboembolic Complications.

 Evaluation Of Fondaparinux (Also Called ARIXTRA) 2.

5 mg Subcutaneously Once Daily For The Treatment Of Superficial Thrombophlebitis (Also Known As Superficial Vein Thrombosis)@highlight

To evaluate fondaparinux 2.

5mg subcutaneously once daily for 45 days in the treatment of acute (recent) superficial thrombophlebitis.

